STAT
SEPTEMBER 14, 2024
BARCELONA, Spain — Patients with advanced cancers often develop a secondary condition that causes them to shed weight, making it even harder to tolerate their cancer treatments. Called cachexia, it’s an under-recognized syndrome that researchers are still trying to tease out, and one that’s attracting more interest from drugmakers.
Fierce Pharma
SEPTEMBER 14, 2024
AstraZeneca’s Imfinzi recently became the first PD-1/L1 inhibitor to deliver a patient survival win in muscle-invasive bladder cancer (MIBC). | AstraZeneca’s detailed data show exactly how Imfinzi became the first PD-1/L1 inhibitor to deliver a patient survival win in muscle-invasive bladder cancer. But the win came from a perioperative regimen, a trial design that’s been criticized by the FDA in lung cancer.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
SEPTEMBER 14, 2024
BARCELONA, Spain — A widely used immunotherapy approach helped stave off disease progression in patients with a type of anal tumor, researchers reported Saturday, potentially setting up the drug for approval in a cancer that’s largely caused by human papillomavirus. The Phase 3 trial tested the PD-1 targeting antibody retifanlimab in combination with chemotherapy versus chemotherapy alone in patients with recurrent or metastatic squamous cell carcinoma of the anal canal.
pharmaphorum
SEPTEMBER 14, 2024
ESMO 2024 began on Friday 13th September. Prof Andres Cervantes discussed how building trust has been a several generation development, following five decades of effort in the oncological space.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pharmacy Times
SEPTEMBER 14, 2024
An ESMO 2024 presentation explores the growing role of the gut microbiome in immunotherapy response, emerging diagnostic tools such as PCR chips, and innovative therapies such as fecal microbiota transplantation and microbiome-preserving strategies to improve patient outcomes.
Drug Topics
SEPTEMBER 14, 2024
Check out this recap of articles published on our sister sites during the past week.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Drug Topics
SEPTEMBER 14, 2024
Check out a recap of important pharmacy news you might have missed this week, dispensed in small doses.
Fierce Pharma
SEPTEMBER 14, 2024
In 2021, the FDA blasted Merck for using a premature endpoint to pursue a Keytruda approval in early-stage triple-negative breast cancer (TNBC). | In 2021, the FDA blasted Merck for using premature data to pursue a Keytruda approval in early-stage triple-negative breast cancer. Now, the PD-1 inhibitor has gold-standard overall survival data to back its case.
Pharmacy Times
SEPTEMBER 14, 2024
The gut and intratumoral microbiota influence cancer development, progression, and treatment responses, highlighting the potential for treatment strategies that leverage these microbial interactions to enhance cancer therapies.
Expert insights. Personalized for you.
136 
Let's personalize your content